


Updates on Cancer Medicines Forum (CMF)

PCWP- HCPWP meeting 18 November 2025

Caroline Voltz-Girolt

Product lead |Scientific secretariat of the Haematology Working Party
|Oncology external engagement coordinator, Office of advanced therapies
and haemato-oncology, EMA



Why was the Cancer Medicines Forum created in 2022?



Unmet medical need in Oncology led to fast medicines approval

Manifesto

for a new approach for better medicine in Europe
Establishing Treatment Optimization
as part of personalized medicine development

(version 29 May 2020)



- Uncertainties at the time of authorization: optimal dose, duration, special population and sequence of treatments, etc...
- Registration trials do not reflect real-world clinical complexity.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH



Medicines ▾ Human regulatory ▾ Veterinary regulatory ▾ Committees ▾ News & events ▾ Partners & networks ▾ About us ▾

Home > Human regulatory: overview > Research and development > Cancer medicines > Cancer Medicines Forum

Cancer Medicines Forum

The European Medicines Agency (EMA) set up the Cancer Medicines Forum to help advance research into optimising cancer treatments and foster high standards in cancer care in the European Union (EU).

Human Medicines


Members

The forum brings together academic organisations from EMA's [Healthcare Professionals Working Party](#) and the [European medicines regulatory network](#). Other members include:

- [European Haematology Association \(EHA\)](#)
- [European Society of Medical Oncology \(ESMO\)](#)
- [European Society for Paediatric Oncology \(SIOPE\)](#)
- [International Society of Geriatric Oncology \(SIOG\)](#)

Observers include health technology assessment bodies, patient and industry organisations, and:

- [Organisation for Economic Co-operation and Development \(OECD\)](#)
- [International Association of Mutuals \(AIM\)](#)
- [European Social Insurance Platform \(ESIP\)](#)



CMF launched by EMA + EORTC to address treatment optimisation gaps.

Non-advisory, multi-stakeholder forum including academia, HTA, payers, and patient reps.



Objectives of the Cancer Medicines Forum



3 years operations – quarterly meetings

Meetings

The forum meets quarterly.

Select the expandable panel below (via the arrow symbol) to access agendas, minutes and meeting materials:

Cancer Medicines Forum: meetings and workshops

- [Cancer Medicines Forum: June 2025](#) (17/06/2025)
- [Cancer Medicines Forum: March 2025](#) (31/03/2025)
- [Cancer Medicines Forum: December 2024](#) (16/12/2024)
- [Cancer Medicines Forum: October 2024](#) (01/10/2024)
- [Cancer Medicines Forum: May 2024](#) (23/05/2024)
- [Cancer Medicines Forum workshop: April 2024](#) (05/04/2024)
- [Cancer Medicines Forum: February 2024](#) (26/02/2024)
- [Cancer Medicines Forum: December 2023](#) (04/12/2023)
- [Cancer Medicines Forum: June 2023](#) (26/06/2023)
- [Cancer Medicines Forum: March 2023](#) (07/03/2023)
- [Cancer Medicines Forum: December 2022](#) (21/12/2022)
- [Cancer Medicines Forum: June 2022](#) (28/06/2022)
- [Cancer Medicines Forum: kick-off meeting](#) (31/03/2022)

Drafted framework for when and how to run optimisation trials


Optimisation positioned to begin during scientific advice pre-authorisation.

EHA, ESMO, and EORTC proposed treatment optimisation questions

Case studies (DE-ESCALATE in prostate cancer, STARBUST in bladder cancer) illustrated benefits of de-escalation for toxicity and affordability.

CMF similar objective to FDA [Project optimus](#), [Project pragmatica](#), [Project 5 in 5](#) and Common Sense Oncology (CSO)

2 Cancer Medicines Forum workshops held in April 2024 and November 2025



CMF workshop held under the Belgian presidency:

- Presenting the objectives and setting the scene
- Treatment optimisation identified during CHMP evaluation (updated CHMP AR template)
- To be made available on EMA website



CMF workshop held to foster interactions between industry and academia:

- Industry support for cancer treatment optimisation both during the development phase and the post-marketing authorisation process
- Advancing cancer research through shared data & samples
- Discussion on reward mechanisms for post-marketing studies from payers
- Agreement on future collaborative work

Next steps: CMF mandate to be established under HCPWP/PCWP

- Agreement on CMF governance and reporting to PCWP/HCPWP
- Formalise membership based on new call for nomination to eligible organization
 - 5 members (up to 2 for each organisations): EORTC, EHA, ESMO, SIOPE and SIOGE
- Formalise list of observers based on new call for nomination to eligible organisations/stakeholders:
 - Proposed 7 observers: industry, patients, SMEs, CROs, devices, HTAs, payers
- Regularly share information and update the PCWP/HCPWP on the CMF activities
- Functioning of the CMF to be reviewed from time to time based on the experience gained



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Thank you

caroline.voltz@ema.europa.eu

Acknowledgements:

Francesco Pignatti

Denis Lacombe

Follow us

